Gracell Biotechnologies Reports Third Quarter 2022 Unaudited Financial Results and Provides Corporate Update
14 nov. 2022 07h15 HE
|
Gracell Biotechnologies Inc.
On track to submit IND filings in U.S. and China for GC012F for the treatment of relapsed/refractory multiple myeloma (RRMM) in the fourth quarter 2022First clinical data from ongoing...
Gracell Biotechnologies Reports Second Quarter 2022 Unaudited Financial Results and Provides Corporate Update
15 août 2022 07h15 HE
|
Gracell Biotechnologies Inc.
Presented updated clinical data from an investigator-initiated trial (IIT) evaluating FasTCAR GC012F for the treatment of relapsed/refractory multiple myeloma (r/r MM) at ASCO and EHA 2022, which...
Gracell Biotechnologies to Participate in the 2021 Virtual Wells Fargo Biotech Corporate Access Day
17 mars 2021 08h00 HE
|
Gracell Biotechnologies Inc.
SUZHOU and SHANGHAI, China, March 17, 2021 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and...